NCT05517980View on ClinicalTrials.gov

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2027

Conditions
Glomerulonephritis
Interventions
DRUG

KP104

Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.

Sponsors
All Listed Sponsors
lead

Kira Pharmacenticals (US), LLC.

INDUSTRY